That’s the wrong question.

The right question is: what does this patient need, at this stage of their disease?

Obesity is chronic, progressive, and heterogeneous. The era of picking a lane — medical or surgical — is over. The best outcomes come from building integrated pathways. Here’s how I think we could think about it clinically.

BMI 27–35: Early intervention, metabolic protection

This is where the newer incretin therapies have genuinely expanded our toolkit. For patients without advanced complications, GLP-1s can achieve meaningful weight loss and delay progression to T2DM, NAFLD, and OSA. The goal here is prevention — getting in early before the disease accumulates damage. Medication earns its place at this stage, and I use it.

BMI 35–45: The judgment zone

No dogma here. This is where clinical decision making meets outcome data.

I’ll consider GLP-1s alone when diabetes is mild or very recently diagnosed and the patient is highly adherent. Endoscopic options when they want a lower-risk bridge with 15% total body weight loss (TBWL). Surgery when there’s severe GERD, significant visceral fat, liver fibrosis, established diabetes or a poor response to medical therapy.

Often the sequence is: surgery for the durability that drugs alone haven’t matched long-term. HbA1c, reflux burden, functional status, and what the patient can realistically sustain for 20 years, cumulative cost of injectables — these also can drive the decision for surgery versus a trial of medication, not the BMI alone.

BMI 45+: Surgery anchors the pathway

The data here hasn’t changed, and it won’t be overturned by a few years of GLP-1 trial data. For severe obesity with end-organ damage — fatty liver disease, refractory T2DM, sleep apnoea, joint destruction — metabolic surgery delivers weight loss and disease remission at a magnitude we cannot replicate pharmacologically with medications available to date. Not yet. Possibly not ever, for this cohort.

That said, GLP-1s have earned a genuine role around surgery: shrinking the liver pre-operatively in very high BMI patients, reducing anaesthetic risk, and rescuing for weight regain long after the operation. They can extend what surgery starts. They don’t replace what surgery does.

What the best programs are building

Stratify by more than BMI — we need to stratify patients by metabolic burden, genetics, psychological readiness, and social context all matter. Sequence therapies deliberately and consider what the correct combinations are based on the stage of the disease. Follow patients for decades, not months. And put surgeons, physicians, dietitians, and psychologists in the same room, sharing the same data.

The tribalism between “medical” and “surgical” camps has cost patients. The win here is designing systems that deliver the right option, to the right patient, at the right moment in their disease trajectory.

That’s precision obesity care. And it needs surgeons to build it.

Your Health. We Care.

The post Knife and Needles appeared first on Blackrock WeightCare.

Will the weight come back?

The honest answer is that weight regain can happen with both treatments. The difference lies in why it happens, how common it is, and how it is managed.

Understanding that difference matters before choosing your next step.

Why Weight Regain Happens After Injections

Medications such as Mounjaro and Ozempic work by regulating appetite hormones and slowing stomach emptying. While you are taking them, appetite is reduced and calorie intake falls.

The challenge is what happens when the medication stops.

These injections do not permanently change the anatomy of the digestive system. Once the medication is withdrawn:

• Appetite hormones gradually return to baseline
• Hunger increases
• Calorie intake rises
• Weight regain can occur

Clinical studies have shown that a significant proportion of weight lost on GLP-1 medications may be regained after stopping treatment if no structured long-term plan is in place.

This means injections need to be continued long term to maintain results. Medication is a lifelong treatment for a chronic disease. That carries a commitment to continuing the medications with clear cost implications and requires ongoing medical supervision.

Why Weight Regain Happens After Bariatric Surgery

Weight regain after surgery is different.

Procedures such as Gastric Sleeve and SADI-S permanently alter stomach size and, in some cases, nutrient absorption. They also create long-lasting hormonal changes that reduce hunger and improve insulin sensitivity.

However, surgery is not immune to weight regain.

Reasons may include:

• Gradual adaptation of the stomach over time
• High-calorie liquid intake
• Grazing behaviour
• Emotional eating
• Reduced follow-up engagement
• Lack of dietary structure

The key difference is that the anatomical and hormonal changes from surgery remain in place. This makes weight regain generally slower and often less dramatic than after stopping injections.

In most cases, surgery provides more durable long-term weight loss, particularly in patients with BMI over 45.

How Much Weight Regain Is Normal

After bariatric surgery, small amounts of weight regain several years later can be normal. The body stabilises after the initial weight loss phase. The goal is not zero regain. The goal is maintaining significant net weight loss and improvement in health.

After stopping injections, weight regain can be more rapid because the hormonal effect is removed entirely.

The pattern is different. The underlying biology explains why.

Which Offers More Durable Results

For patients with severe obesity, especially BMI above 40, bariatric surgery consistently shows stronger and more durable long-term outcomes compared to injections alone.

Injections can be effective for moderate obesity. They are valuable tools. But they do not currently match the long-term metabolic impact of surgery in higher BMI groups. That does not mean injections have no role. In some patients, they are appropriate as:

• A primary treatment
• A bridge before surgery
• Support in cases of mild post-surgical regain

For many patients the treatment of their obesity may involve both – often surgery now and medication later if ever required.

The decision depends on the individual.

What Happens if Weight Regain Occurs

At Blackrock WeightCare, weight regain is managed proactively.

This may include:

• Nutritional review
• Behavioural support
• Medical optimisation
• Use of medication where appropriate
• Consideration of revisional surgery in selected cases

Mr William Robb assesses each situation carefully. As an Upper GI and Robotic Bariatric Surgeon, he evaluates anatomical, metabolic and behavioural factors before recommending next steps.

The focus is always on long-term health, not short-term numbers.

The Bigger Question

The real question is not whether weight regain is possible. It is which treatment offers the most sustainable control of a chronic disease.

Obesity is a long term chronic disease. It requires a long-term plan and an ever evolving algorithm of care.

Injections require ongoing use to maintain effect. Surgery creates permanent anatomical and hormonal changes that support durability, particularly in higher BMI patients.

Neither is a quick fix. Both require commitment and follow-up.

Choosing the Right Path

If you are concerned about weight regain, whether after injections or surgery, the right step is expert assessment before making changes.

At Blackrock WeightCare, complex and high BMI patients are routinely assessed to determine the safest and most effective long-term strategy.

To know more, click here and fill the enquiry form or speak directly with our team on 01 255 2479.

Your Health. We Care.

The post Weight Regain After Injections vs Bariatric Surgery: What is the Difference appeared first on Blackrock WeightCare.

How Weight Loss Injections Work

Weight loss injections, also known as GLP-1 medications, mimic hormones that control appetite and blood sugar. By slowing digestion and helping you feel fuller for longer, they reduce overall food intake. Many patients notice weight loss within the first few months, and injections can also help manage type 2 diabetes and improve cardiovascular health.

However, injections must be taken regularly to maintain results. Once treatment stops, weight regain is very common. Studies also show that total weight loss from injections is often far less than what is achieved through surgery.

The Limits of Injections

• Short-term tool: Most patients lose around 10–15% of their body weight on injections, but results often plateau.

• Ongoing cost: Injections are expensive and must be continued long-term to maintain results.

• Not a cure: They help manage appetite but do not resolve the root causes of obesity or the health issues linked with it.

For patients with a BMI over 40, injections on their own rarely provide enough weight loss to resolve serious health conditions such as sleep apnoea, uncontrolled diabetes, or high blood pressure.

Why Surgery Is the Better Choice for Higher BMI

Bariatric surgery, including gastric bypass, sleeve gastrectomy, and SADI-S, consistently delivers more significant and lasting results.

• Greater weight loss: On average, patients lose 60–70% of excess body weight after surgery.

• Durable outcomes: Weight loss is maintained for many years when paired with aftercare.

• Health benefits: Surgery often improves or even resolves type 2 diabetes, hypertension, and other obesity-related conditions.

• Longer life expectancy: Research shows that bariatric surgery can add years of healthy life, especially for patients with type 2 diabetes.

At Blackrock WeightCare, patients also receive a two-year structured aftercare programme with dietitians, endocrinologists, nurse specialists, and 24/7 clinical support. This ensures that surgery is not just about losing weight, but about building a healthier, more confident life.

When Injections May Still Help

Injections can play a role for patients who:

• Have a BMI below 35 and are not eligible for surgery.

• Need to lose weight before surgery to reduce surgical risks.

• Are looking for a temporary aid while preparing for a long-term solution.
• After surgery for patients who experience insufficient weight loss or later down the line experience weight gain

But for patients with a BMI above 35, injections alone are unlikely to achieve the same results as surgery for meaningful and lasting health improvements.

Weight loss injections can be a helpful option for some people, but they do not replace the need for surgery in patients with higher BMI. If your BMI is 35 or above, the most effective and lasting treatment is bariatric surgery, supported by comprehensive aftercare.

At Blackrock WeightCare, we meet patients from all across Ireland who are considering their options for lasting weight loss and better health. What we often find is that if someone has a BMI of 40 or above and starts on injections, they may lose around 10–15% of their weight. While that is a positive step, it usually does not bring them into a healthy BMI range. The challenge then is that they may no longer meet the criteria for bariatric surgery under insurance, which can leave them in a difficult position of depending on injectables in the long-term without access to the more permanent solution of surgery.

For this reason, it can be wise to check with a bariatric surgeon before deciding whether injections or surgery are the right choice. General advice or information online may not fully apply to your own situation, and a consultation will give you clear, personalised guidance.

Every patient’s journey is unique, and at Blackrock WeightCare we are here to support you in finding the safest and most effective path for your health and long-term success. With world-class medical expertise and a dedicated support team, we are here to guide you through every step of your journey.

Your Health. We Care.

The post Do Weight Loss Injections Eliminate the Need for Surgery? appeared first on Blackrock WeightCare.

Bariatric and Upper Gastrointestinal Surgeon, Blackrock Clinic, Dublin, Ireland

Obesity has at last been recognised as a chronic illness and disease which results from the accumulation of excessive body fat which in turn can damage health. No more should the stigma of laziness and the “it’s your fault” culture be accepted. Attitudes towards the disease of obesity, and patients suffering from its consequences, have and will continue to change, evolve and modernise.

Thankfully the medical world has awoken to the realisation that, as with any chronic illness, effective treatment strategies are required. The old dogma of ‘move more and eat less’ is a failed concept and evidence is strong that, just like any chronic illness, effective therapy is needed. Surgery has been at the cornerstone of treatment but is medical therapy catching up?

Until recently obesity has been defined as having a body mass index (BMI) of 30 or greater. Trends and projections for the levels of obesity are alarming and obesity is a major risk factor for several chronic diseases, including heart disease, stroke, type 2 diabetes, and certain types of cancer.

The relationship between health and weight is not however a simple and linear one. Many patients with an elevated BMI may not have developed the consequences of their excess weight whilst others with a BMI of a much lower level may develop metabolic consequences including diabetes, hypertension and obstructive sleep apnoea amongst others. So as knowledge evolves, simply measuring BMI has become an outdated means of defining what constitutes the disease of obesity. Nevertheless, this measure continues to provide guidance and a practical measure for patients and clinicians alike.

Of course, a healthy lifestyle is to be encouraged for all. The diet and exercise industries have their place but they do not provide the answer to the growing obesity epidemic which faces society. It is an epidemic which from all predictions is only set to worsen in the years ahead. It is estimated that approximately 30% of adults in the United States are obese. In my own country, Ireland, figures from the World Health Organisation suggest 89% of Irish men are set to be overweight by 2030 while obesity rates for women are set to soar from 24 to 57% of the population.

Healthcare costs associated with treating the metabolic syndrome that obesity sets in motion are mounting exponentially and remain underestimated in many societies. Effective treatment has been repeatedly shown to improve a population’s health with significant cost efficiencies for healthcare systems. Effective treatment of obesity results in the resolution of many of the health consequences it brings. Diabetes, hypertension, chronic liver disease, and sleep apnoea may be significantly improved or resolved and there is a reduction in the risk of developing a number of cancers. So, along with the health benefits, the economic benefits are self-evident.

In the last number of years, there has been much hype over the potential of several weight loss medications.

Ozempic (semaglutide) is the best known of these and has become so popular because it makes people lose weight effectively and quickly. Social media is rife with its promotion. Rumours of its use amongst celebrities and social media influencers has driven curiosity. It’s a once-weekly injection that can help lose weight and keep it off.

Seems simple.

Ozempic for weight loss works by mimicking a naturally-occurring hormone called GLP-1. GLP-1 is responsible for regulating appetite and blood sugar levels. When levels of GLP-1 are low, you may experience increased hunger and cravings. Ozempic helps to regulate these levels, which then can result in reduced hunger and fewer cravings, with slower gastric (stomach) emptying, all ultimately leading to weight loss.

Initial evidence for its use came in the SUSTAIN clinical trials where semaglutide consistently demonstrated in patients with type II diabetes and obesity that blood sugar control was improved and participants lost weight. It was also found to reduce cravings for food and appetite. Weight control in diabetics is incredibly important as excess body fat drives resistance to insulin which results in poor blood glucose control. Further, weight loss can lead to the resolution of this disease, normalising a patient’s blood sugars and removing the requirement for medication. The health and cost benefits are clear.

Further evidence of semaglutide’s role in weight management in patients who do not have diabetes has come from the Semaglutide Treatment Effect in People with Obesity (STEP) program. Once-weekly injections with semaglutide at a dose of 2.4mg resulted in weight loss of 14.9 % from baseline after 68 weeks. Two-year results were reported in the STEP 5 trial results. The primary endpoints in this trial were the percentage change in body weight and additionally achievement of weight loss of >5% after 2 years of treatment. Of 304 participants randomly assigned to receive either semaglutide 2.4mg or a placebo (a dummy treatment) most (77.6%) were female, the average age was 47.3 years and the average BMI was 38.5kg/m². The results saw an impressive 15.2% mean change in body weight in the treatment group receiving ozempic.

An important distinction needs to be made between the treatment of patients who have the disease of obesity and those people who simply wish to use this drug for weight loss to conform to a perception of what is a socially acceptable weight and the ongoing cultural desire to be thin.  Treating people can reverse the metabolic syndrome that obesity brings but it requires patients to be prepared to take this treatment indefinitely and perhaps for the rest of their lives.

Paradoxically, if it is used by people with a simple desire to be thinner, they will lose weight initially whilst on treatment but when it is stopped they will very likely regain all the weight and may rebound to a weight higher than they were at the outset. As a simple weight loss medication its use may not be a good idea as most patients are unlikely to wish to be on lifelong treatment.

So, it becomes increasingly clear that what matters most is whether excess weight is compromising health, confirming a diagnosis of the disease of obesity. Treatments should be primarily directed at this group.

Just like the emphasis of surgical treatment should not be about measuring weight loss but rather maximising health gain, the same must be also true of medical and pharmacological treatment of obesity.

The post Is Semaglutide (Ozempic) all it seems? – Horizons in Obesity Medicine appeared first on Blackrock WeightCare.